ClinicalTrialsFinder
RecruitingNot ApplicableNCT07418450

Discrimination of N2a and N2b by EBUS-TBNA: is a Change of the Needle Necessary?

Discrimination of N2a and N2b by EBUS-TBNA: is a Needle Change Necessary? - a Prospective Pilot Study

Sponsor

University of Vienna

Enrollment

30 participants

Start Date

Nov 5, 2025

Study Type

INTERVENTIONAL

Conditions

Lung Cancer (Diagnosis)

Summary

During EBUS staging in patients with mediastinal lymphadenopathy, it is planned to perform a first round of staging with change of the needle between all lymph nodes and a second round of staging without change of the needle.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study looks at whether doctors can reliably distinguish between two types of lung cancer lymph node involvement — N2a (a single lymph node station affected) and N2b (multiple stations affected) — using a bronchoscopy-guided needle biopsy technique called EBUS-TBNA (endobronchial ultrasound transbronchial needle aspiration), and whether changing the needle between stations is necessary. **You may be eligible if...** - You have a lung lesion suspicious for lung cancer, or you have been confirmed to have lung cancer - You need staging of the lymph nodes in the middle of your chest (mediastinal staging) **You may NOT be eligible if...** - You do not require mediastinal staging Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTEBUS-TBNA

During EBUS staging, the needle well be changed between all lymph node stations in a first round. The EBUS staging will be repeated without the change of the needle between the lymph node stations.

Locations(1)

Medical University of Vienna

Vienna, Austria

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07418450

Related Trials

Blood Based Risk Evaluation With AI for Targeted Primary Health Care in Early Lung Cancer Detection

NCT075525842 locations

Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.

NCT071689933 locations

Prospective Multicentre Study for the Application of Telomere Measurement Technology as a Tool for Lung Cancer Diagnosis

NCT0746584812 locations

Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery

NCT074399911 location

EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

NCT074106761 location